Simultaneously, immune checkpoint inhibitors (ICIs) targeted to the programmed death ligand-1 (PD-L1) expressed by tumor cells would also contribute to prolonged overall survival (OS) in PD-L1-positive patients with advanced NSCLC [6, 7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.